doxycycline | Unidox Solutab tablets dispersible 100 mg 10 pcs.

Release form

Dispersible tablets.

Packing

10 pcs.

Pharmacological action

Broad-spectrum antibiotic from the tetracycline group. It acts bacteriostatically, inhibits protein synthesis in a microbial cell by interacting with the 30S subunit of ribosomes.

Active against many gram-positive and gram-negative microorganisms: Streptococcus spp., Treponema spp., Staphylococcus spp., Klebsiella spp., Enterobacter spp. (including E. aerugenes), Neisseria gonorrhoeae, Neisseria meningitidis, Haemophilus influenzae, Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum, Listeria monocytogenes, Rickettsia spp., Typhus exanthematicus, Shigeribi coli coli campiella colibella Yersinia spp. (including Yersinia pestis), Brucella spp., Francisella tularensis, Bacillus anthracis, Bartonella bacilliformis, Pasteurella multocida, Borrelia recurrentis, Clostridium spp. (except Clostridium difficile), Actinomyces spp., Fusobacterium fusiforme, Calymmatobacterium granulomatosis, Propionibacterium acnes, some protozoa (Entamoeba spp., Plasmodium falciparum).

Generally does not affect Acinetobacter spp., Proteus spp., Pseudomonas spp., Serratia spp., Providencia spp., Enterococcus spp.

The possibility of acquired resistance to doxycycline in a number of pathogens, which is often cross-within the group (i.e., doxycycline resistant strains will be resistant to the entire tetracycline group at the same time), should be taken into account.

Indications

Infectious and inflammatory diseases caused by microorganisms sensitive to the drug:

- respiratory tract infections (including pharyngitis, acute bronchitis, exacerbation of chronic obstructive pulmonary disease, tracheitis, bronchopneumonia, lobar pneumonia, community-acquired pleural empyema)

- infections of the ENT organs (including otitis media, sinusitis, tonsillitis)

- infections of the genitourinary system (cystitis, pyelonephritis, bacterial prostatitis, urethritis, urethrocystitis, urogenital mycoplasmosis, os ing orhiepididimit endometritis, salpingo endocervite and / as part of combination therapy /)

- infections, sexually transmitted infections (urogenital chlamydia, syphilis in patients with intolerance to penicillins, uncomplicated gonorrhea / as an alternative therapy / inguinal granuloma, venereal lymphogranuloma)

- infections of the gastrointestinal tract and biliary tract (cholera, yersiniosis, cholecystitis, cholangitis, gastroenterocolitis, bacillary and amoebic dysentery, travelers diarrhea)

- infections of the skin and soft tissues (including wound infections) after severe wound infections disease (as part of combination therapy)

- other diseases: frambesia, legionellosis, chlamydia of various localization (including prostatitis and proctitis), rickettsiosis, Q fever, Rocky Mountain spotted fever, typhoid (including rash , tick-borne relapsing), Lyme disease (stage I) - erythema migrans /, tularemia, plague, actinomycosis, malaria, leptospirosis, psittacosis, ornithosis, anthrax (including pulmonary form), bartonellosis, granulocytic ehrlichiosis, whooping cough, brucellosis

- infectious diseases of the eyes (as part of combination therapy) - trachoma

- osteomyelitis

- sepsis

- subacute septic endocarditis

- peritonitis.

Prevention of postoperative purulent complications and malaria caused by Plasmodium falciparum during short trips (less than 4 months) in the territory where strains resistant to chloroquine and / or pyrimethamine sulfadoxine are common.

Contraindications

- severe liver and / or kidney dysfunction

- porphyria

- pregnancy

- lactation (breastfeeding)

- children under 8 years of age

- hypersensitivity to tetracycline antibiotics.

Use during pregnancy and lactation

Doxycycline crosses the blood-placental barrier.

Tetracyclines have an adverse effect on the fetus (slowing down osteogenesis) and on the formation of tooth enamel (irreversible discoloration, hypoplasia).

Due to this, as well as the increased risk of maternal liver damage, tetracyclines are not used during pregnancy, unless the drug is the only way to treat or prevent especially dangerous and severe infections (spotted rocky fever, inhaled exposure to Bacillus anthracis and others).

Before prescribing doxycycline to women of childbearing age, pregnancy should be excluded beforehand.

Doxycycline passes into breast milk. Due to the adverse effects on the fetus, doxycycline, like other tetracyclines, is not used during breastfeeding. If the appointment of tetracyclines is necessary, breastfeeding should be discontinued.

Composition of

Doxycycline monohydrate, in terms of doxycycline 100 mg.

Excipients:

microcrystalline cellulose - 45 mg,

saccharin - 10 mg,

hyprolose (low substituted) - 18.75 mg,

hypromellose - 3.75 mg,

silicon dioxide colloidal (anhydrous) - 0.625 mg,

magnesium stearate - 2 mg,

lactose monohydrate 250 mg.

Side effects of the

Digestive system: anorexia, nausea, vomiting, dysphagia, diarrhea, enterocolitis, pseudomembranous colitis, esophagitis, esophageal ulcer, dark staining of the tongue, liver damage (during prolonged use or in patients with renal or hepatic insufficiency), cholestasis.

Dermatological reactions: photosensitization, maculopapular and erythematous rash, exfoliative dermatitis.

Allergic reactions: urticaria, angioedema, anaphylactic reactions, exacerbation of systemic lupus erythematosus, pericarditis, a syndrome similar to serum sickness, erythema multiforme.

From the hemopoietic system: hemolytic anemia, thrombocytopenia, neutropenia, eosinophilia, a decrease in prothrombin activity.

From the endocrine system: in patients who have been taking doxycycline for a long time, a reversible dark brown staining of the thyroid tissue is possible.

From the side of the central nervous system: benign increase in intracranial pressure (anorexia, vomiting, headache, swelling of the optic nerve), vestibular disorders (dizziness or instability), blurred vision, double vision.

From the urinary system: increased residual urea nitrogen (due to the anti-anabolic effect).

From the musculoskeletal system: doxycycline slows down osteogenesis, disrupts the normal development of teeth in children (irreversibly changes the color of teeth, enamel hypoplasia develops).

Other: candidiasis (glossitis, stomatitis, proctitis, vaginitis) as manifestations of superinfection.

Drug interactions

Antacids containing aluminum, magnesium, calcium, iron preparations, sodium bicarbonate, magnesium laxatives reduce the absorption of doxycycline, so their use should be separated by a 3-hour interval.

Due to the suppression of intestinal microflora by doxycycline, the prothrombin index decreases, which requires dose adjustment of indirect anticoagulants.

When combining doxycycline with bactericidal antibiotics, disturbing the synthesis of the cell wall (penicillins, cephalosporins), the effectiveness of the latter decreases, which should be taken into account in the treatment of meningitis and tonsillopharyngitis caused by Streptococcus pyogenes.

Doxycycline reduces the reliability of contraception and increases the frequency of acyclic bleeding when taking estrogen-containing hormonal contraceptives.

Ethanol, barbiturates, rifampicin, carbamazepine, phenytoin, accelerating the metabolism of doxycycline, reduce its concentration in blood plasma.

The simultaneous use of doxycycline and retinol contributes to an increase in intracranial pressure.

Overdose

Symptoms: increased adverse reactions, caused by liver damage - vomiting, fever, jaundice, azotemia, increased levels of transaminases, increased prothrombin time.

Treatment: Immediately after taking large doses, gastric lavage, heavy drinking, and induction of vomiting are recommended. Accepted activated carbon and osmotic laxatives. Hemodialysis and peritoneal dialysis are not recommended due to low efficacy.

Storage conditions

The product should be stored out of the reach of children at temperatures between 15 ° and 25 РC.

Shelf life

5 years.

Deystvuyushtee substance

Doxycycline

dosage form

tablets soluble